PepGen Inc (PEPG) Stock Forecast & Price Target

PepGen is supported by a differentiated PGN-EDODM1 profile that appears to extend beyond the Novartis HARBOR miss, with broader multi-tissue reach, nuclear delivery via steric block, and the potential for splicing correction beyond the ±20% natural-history band already seen in FREEDOM SAD. The company’s 1Q26 update also showed GAAP EPS of $(0.26) versus consensus $(0.31) and cash/equivalents of $132M, with runway into 2H27, while the 10 mg/kg dosing cohort completed enrollment, keeping the clinical story advancing. If upcoming data confirm ≥30% mean splicing at 10 mg/kg, the stock could benefit from stronger evidence for functional endpoints and a continued accelerated-approval path, despite the partial clinical hold and possible dilution later this year.

PepGen is a high-risk clinical-stage biotech whose valuation depends heavily on a narrow set of catalysts, especially the FREEDOM2 10mg/kg data cohort readout in 2H26, while its PGN-EDODM1 launch is not assumed until FY30. Fundamentally, the company faces major regulatory uncertainty because accelerated approval may still require additional or longer studies, and weaker labels could limit market traction; safety is also pivotal, since dose escalation and eventual efficacy will hinge on tolerability. Commercial execution remains unproven, competition is expected to intensify across branded and generic players, and the need for additional external funding raises dilution and development-delay risk if capital markets become less supportive.